Dr Faizan Kashif, Dr Rizwana Kousar, Dr Rabia Tabassum
Colorectal cancer (CRC) is the second most common cancer type in the Western world, accounting for approximately 450,000 new cases in Europe each year. The basic aim of the study is to find the personalized treatment in patients with colorectal liver metastases in Pakistan. This cross-sectional study was conducted at Punjab Health Department during June 2019 to December 2019. This study was done basically due to analysis of personalized treatment of colorectal liver metastases in Pakistan. We collected the data through pubmed and literature review analysis. It is concluded that personalized medicine has made some major advances in CRC, with KRAS testing now part of routine clinical practice. However, KRAS has some limitations as a biomarker and despite extensive research into other biomarkers for antiangiogenic drugs, chemotherapy and other targeted agents, these are not yet established in clinical practice.